Synthon B.v.

Rohit Kumar

Lisardo Alvarez Fernandez

Luis Nogueiras Nieto

Jose Velada Calzada

Marta Vivancos Martinez

Manuel Gago Guillan

Sara Fradera Gelabert

Petr Mitas

Agnes Fernandez Pena

Bohumil Dymacek

Lisardo ÁLvarez FERNÁNDEZ

José Velada Calzada

Manolo Gago Guillan

The present invention relates to a film-coated swallowable tablet comprising eltrombopag bis(monoethanolamine) and pharmaceutically acceptable excipients comprising calcium silicate as diluent. The invention further relates to the use of said tablet as a medicament, particularly in the treatment of immune thrombocytopenia (ITP), thrombocytopenia in patients with chronic hepatitis C virus (HCV) and severe aplastic anaemia (SAA).

Pharmaceutical composition comprising eltrombopag bis(monoethanolamine)

The present invention relates to an immediate release tablet composition comprising axitinib form IV characterized by an XRPD pattern comprising the peaks at about 8.9, 12.0, 14.6, 15.2, 15.7, 17.8, 19.1, 20.6, 21.6, 23.2, 24.2, 24.9, 26.1 and 27.5±0.1 degrees 2θ, when measured with Cu Kα1 radiation and one or more pharmaceutically acceptable excipients, wherein the composition exhibits a dissolution rate between 40% and 70% in 30 minutes when tested in 900 ml 0.01 N hydrochloric acid pH 2.0 at 37° C., 75 rpm in a USP apparatus II.

Pharmaceutical composition comprising axitinib

The present invention relates to a pharmaceutical composition comprising a therapeutically effective dose of Lenvatinib mesylate having sodium wherein the weight ratio of Lenvatinib mesylate to sodium carbonates ranges from 1:1.5 to 1:5.

Pharmaceutical composition comprising Lenvatinib mesylate

The present invention relates to a tablet composition for oral administration of abiraterone acetate, particularly to pharmaceutical granulates and tablets giving immediate release of abiraterone acetate in the stomach.

Tablet compositions comprising abiraterone acetate

The present invention relates to a pharmaceutical granulate composition comprising Palbociclib free base, having improved bioavailability.

Pharmaceutical composition comprising Palbociclib

The present invention relates to a tablet composition comprising ibrutinib and one or more pharmaceutically acceptable excipients, characterized in that: The invention further relates to the use of said composition as a medicament, particularly in the treatment of chronic lymphocytic leukaemia (CLL), mantle cell lymphoma (MCL) and Waldenstr&#xf6;m's macroglobulinaemia (WM).

Pharmaceutical composition comprising ibrutinib

The present invention relates to a pharmaceutical composition comprising a physical mixture of sacubitril sodium and valsartan disodium, wherein the X-ray powder diffraction pattern of valsartan disodium comprises characteristic peaks at the following 2 theta (&#xb1;0.2) angles: 4.70&#xb0;, 9.29&#xb0;, 22.34&#xb0;, measured using a Cu K&#x3b1; radiation. The invention further relates to the use of said pharmaceutical composition as medicament in the treatment of heart failure.

Pharmaceutical composition comprising sacubitril and valsartan

The present invention relates to a pharmaceutical composition, particularly a modified release tablet composition comprising mirabegron or a pharmaceutically acceptable salt thereof and to a process for preparing such a composition.

Growing community of inventors

Sant Boi de Llobregat, Spain

Rohit Kumar